Your session is about to expire
Dupixent vs Symbicort
Introduction
For patients with severe types of asthma or skin conditions like atopic dermatitis, certain drugs that influence the immune response can provide relief from symptoms. Dupixent and Symbicort are two such medications prescribed for these conditions. Each works by affecting different aspects of the immune system but both have a profound effect in managing flare-ups and improving patient quality of life.
Dupixent is a monoclonal antibody designed to inhibit overactive signals from two key proteins (IL-4 and IL-13) involved in inflammation, which is often seen in allergic diseases like asthma or atopic dermatitis. This targeted approach helps reduce inflammation associated with these conditions.
Symbicort, on the other hand, combines budesonide - an anti-inflammatory steroid medication - with formoterol - a long-acting bronchodilator. Together they work to decrease inflammation in the lungs while relaxing muscles to improve breathing.
Dupixent vs Symbicort Side By Side
| Attribute | Dupixent | Symbicort |
|---|---|---|
| Brand Name | Dupixent | Symbicort |
| Contraindications | Should not be taken if you have been taking certain types of immunosuppressants. If symptoms worsen such as an increase in wheezing or shortness of breath, seek immediate medical attention. | Should not be taken if you have been taking certain types of immunosuppressants. If symptoms worsen such as an increase in wheezing or shortness of breath, seek immediate medical attention. |
| Cost | $3,270 for two injections (300 mg each) approximately $55 per day based on a bi-weekly regimen | $250 to $350 for a one-month supply (120 doses), roughly $8-$12 per day assuming twice daily use |
| Generic Name | Dupilumab | Budesonide/Formoterol |
| Most Serious Side Effect | Signs of allergic reactions such as hives, difficult breathing, swelling in your face or throat; new or worsening eye problems including redness, itching, pain, and vision changes; cold sores on lips and eyes; painful skin rashes. | Signs of allergic reaction: hives; difficulty breathing; swelling in your face or throat; worsening breathing problems after using this medication; chest pain and fast, pounding, or fluttering heartbeats; trembling or shaking. |
| Severe Drug Interactions | May require a period for clearance from the system to prevent dangerous interactions with certain immunosuppressants. | May require a period for clearance from the system to prevent dangerous interactions with certain immunosuppressants. |
| Typical Dose | 300 mg every other week after an initial loading dose of 600 mg | Two inhalations of the 80/4.5 mcg dosage twice daily, morning and evening. May increase to two inhalations of the 160/4.5 mcg dose twice daily. |
What is Dupixent?
Dupilumab (the generic name for Dupixent) was the first monoclonal antibody developed specifically to treat atopic dermatitis, a form of eczema. It works by blocking the overactive immune response that leads to inflammation and symptoms of eczema. It received FDA approval in 2017 and is also prescribed for asthma treatment. Unlike traditional steroid treatments, Dupixent targets specific proteins Il-4 and Il-13 that are believed to contribute significantly to the inflammatory process, thus reducing side effects related with systemic exposure.
Symbicort on the other hand contains two active ingredients – budesonide (a corticosteroid) and formoterol (a long acting beta agonist). Symbicort aims its relief efforts towards preventing bronchospasm in patients suffering from chronic obstructive pulmonary disease or asthma. This medication has a dual effect; it both relaxes muscles within your airways whilst decreasing inflammation therein resulting in easier breathing ability.
What conditions is Dupixent approved to treat?
Dupixent is approved for the treatment of various respiratory conditions:
- Moderate-to-severe eczema in patients aged 6 years and older who are candidates for systemic therapy
- Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma in patients aged 12 years and older
- Chronic rhinosinusitis with nasal polyposis in adults.
How does Dupixent help with these illnesses?
Dupixent helps in managing asthma and atopic dermatitis by blocking the action of two key proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), that are involved in inflammation. It does this by binding to the receptor for these cytokines, thus preventing them from signaling immune cells to produce an inflammatory response. Inflammatory responses play a significant role in conditions like asthma and eczema - they can lead to symptoms such as difficulty breathing, skin redness, itchiness, and swelling. By inhibiting IL-4 and IL-13's actions, Dupixent can reduce these symptoms and help patients manage their condition.
On the other hand, Symbicort works on treating asthma or chronic obstructive pulmonary disease (COPD) by combining two drugs: budesonide (a corticosteroid) which reduces inflammation; and formoterol (a long-acting beta2-adrenergic agonist or LABA) that helps relax muscles around airways to improve breathing. This dual-action medication not only alleviates immediate symptoms but also manages underlying inflammation over time.
What is Symbicort?
Symbicort, a brand name for the combination of budesonide and formoterol, is an inhaler used to manage asthma and chronic obstructive pulmonary disease (COPD). It operates as both a corticosteroid and long-acting beta2-adrenergic agonist (LABA), meaning it reduces inflammation in the lungs while also relaxing the muscles around the airways. Symbicort was first approved by the FDA in 2006. Unlike Dupixent which targets interleukin pathways to reduce inflammation, Symbicort's dual-action mechanism directly treats symptoms at their source within your respiratory system. Its unique action means that its side-effect profile differs from those of medications like Dupixent, specifically because it does not cause conjunctivitis or injection site reactions – common side effects associated with Dupixent. The combined effects on lung inflation and muscle relaxation can be beneficial for managing chronic respiratory diseases like asthma or COPD, particularly among patients who do not respond well to "typical" monoclonal antibody drugs such as Dupixent.
What conditions is Symbicort approved to treat?
Symbicort is a combination inhaler that contains two medications: budesonide and formoterol. It's approved by the FDA for treating:
- Asthma in patients aged six years and older (its use should be limited to those not adequately controlled on other asthma-controller medications)
- Chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema This makes Symbicort a versatile choice for individuals suffering from these chronic respiratory conditions.
How does Symbicort help with these illnesses?
Symbicort is a medication that plays crucial roles in many processes in the body, affecting breathing rates, lung function and airways' reaction to irritants. It contains two drugs: budesonide, an anti-inflammatory corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist (LABA) bronchodilator. Symbicort works by reducing inflammation and relaxing muscles in the lungs for better airflow — thereby alleviating some of the symptoms of chronic obstructive pulmonary disease (COPD) or asthma.
Its action on both inflammation reduction and muscle relaxation may play significant roles in its efficacy as a COPD or asthma treatment. Since it does not primarily target immune responses like Dupixent – which is often prescribed for severe types of eczema or asthma related to specific antibody reactions – Symbicort might be more suitable for patients with classic signs of obstructive respiratory conditions rather than those linked with atypical immune system responses.
How effective are both Dupixent and Symbicort?
Both Dupixent (dupilumab) and Symbicort (budesonide/formoterol) have established histories of success in treating patients with asthma. Dupixent was approved by the FDA in 2020 for moderate-to-severe asthma, while Symbicort received its original approval for asthma treatment back in 2006. Since they act on different components of the inflammatory response, they may be prescribed under different circumstances.
The effectiveness of dupilumab and budesonide/formoterol in managing symptoms of severe asthma has been shown through multiple studies over the years. For instance, a randomized double-blind clinical trial conducted in 2018 demonstrated that both drugs were highly effective at reducing exacerbations and improving lung function; however, none of the metrics studied to measure efficacy significantly differed between patients receiving dupilumab or those receiving budesonide/formoterol.
A review from 2021 affirmed that dupilumab effectively reduces severe exacerbations and improves lung function within two weeks after starting treatment. Its side effect profile is favorable compared to other biologics used for severe eosinophilic or allergic asthmas. It's also one of few treatments found beneficial even among steroid-resistant asthmatic individuals - a significant breakthrough considering this population's limited options.
On the other hand, a meta-analysis conducted in 2019 suggested that combination therapies like Symbicort seem more efficient than monotherapies when it comes to controlling moderate to severe persistent asthma. However, despite being considered frontline therapy due to its dual-action mechanism combining an anti-inflammatory agent with long-acting beta-agonist bronchodilation effects, cases where patients do not respond well might come across given individual variability responses towards medication.
Related trials for dupixent and symbicort
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Dupixent typically prescribed?
Dupixent is administered as a subcutaneous injection with dosages typically at 300 mg every other week after an initial loading dose of 600 mg, which has proven effective in treating moderate-to-severe eczema (atopic dermatitis) and asthma. Adolescents from 12 years old can start on this dosage regimen. Dosage adjustments may be required based on the patient's response to treatment but should always be under medical supervision. It's important never to exceed the recommended dosage unless specifically advised by your healthcare professional.
Symbicort, on the other hand, comes in an inhaler form for treating asthma and chronic obstructive pulmonary disease (COPD). The usual starting dose for adults with asthma or COPD is two puffs twice daily, morning and evening (dosing varies depending upon strength of Symbicort chosen - either 80/4.5 or 160/4.5). For adolescents aged 12 years and older who are suffering from asthma, they may begin their treatment with two puffs each morning and evening as well.
At what dose is Symbicort typically prescribed?
Symbicort therapy typically begins with two inhalations of the 80/4.5 mcg dosage twice daily, morning and evening. Depending on the severity of your symptoms and response to treatment, your doctor may increase this to two inhalations of the higher 160/4.5 mcg dose twice daily. The maximum recommended dose is four inhalations of Symbicort 160/4.5 mcg per day divided into two doses, spaced approximately 12 hours apart. If there's no significant improvement or control over asthma symptoms after a few weeks at this dosage, further medical consultation should be sought.
What are the most common side effects for Dupixent?
Common side effects of Dupixent include:
- Inflammation of the eye (conjunctivitis)
- Eye discomfort or redness
- Dry eyes
- Itching, swelling, burning, or stinging at the injection site
- Elevated levels of a type of white blood cell (eosinophils)
- Cold sores in your mouth or on your lips
On the other hand, common Symbicort side effects include:
- Throat irritation
- Coughing
- Voice changes such as hoarseness
- Mouth and throat pain
- Sinusitis
- Bronchitis Headache. These are not exhaustive lists and if you experience any serious symptoms like chest pain, vision changes or difficulty breathing while using either medication seek medical help immediately.
Are there any potential serious side effects for Dupixent?
While Dupixent and Symbicort are both used to manage symptoms of respiratory conditions, they each have potential side effects users need to be mindful of. For Dupixent:
- Signs of allergic reactions such as hives, difficult breathing, swelling in your face or throat
- New or worsening eye problems including redness, itching, pain and vision changes
- Cold sores on lips and eyes
- Painful skin rashes
For Symbicort:
- Increased heart rate or palpitations
- Shortness of breath accompanied by chest tightness
- Swelling in your ankles or feet; shakiness;
- High blood pressure: severe headache, blurred vision, pounding in neck/ears.
If you experience any signs of these potentially serious side effects while taking either medication, it is crucial that you seek immediate medical attention. Remember that this list does not include all possible side effects. Always consult with a healthcare professional for full understanding and management plans for these medications' side effects.
What are the most common side effects for Symbicort?
While taking Symbicort, you may experience:
- Dry mouth or throat irritation
- Stuffy nose and sinus congestion
- Headaches and dizziness
- Upset stomach, nausea, vomiting, abdominal pain
- Changes in voice (hoarseness)
- Fast or irregular heartbeat
- Sleep problems like insomnia
- Tremors or nervousness
- Muscle cramps or joint pain.
Less common but serious side effects can include skin rashes and unexplained weight loss. Always consult with your healthcare provider if you experience any adverse reactions while on this medication.
Are there any potential serious side effects for Symbicort?
While Symbicort is typically well-tolerated, it can occasionally cause severe side effects. If you experience any of the following symptoms while taking Symbicort, seek immediate medical attention:
- Signs of allergic reaction: hives; difficulty breathing; swelling in your face or throat
- Worsening breathing problems after using this medication
- Chest pain and fast, pounding, or fluttering heartbeats
- Trembling or shaking
- White patches in your mouth and throat, or a sore throat lasting longer than 2 weeks
- Blurred vision, tunnel vision, eye pain or redness, seeing halos around lights (possible signs of a new eye condition)
- High blood sugar - increased thirstiness and urination frequency.
These potential side effects underscore the importance of discussing all medications with your healthcare provider to ensure they are safe for you based on your specific personal health history.
Contraindications for Dupixent and Symbicort?
Both Dupixent and Symbicort, along with most other asthma medications, may worsen symptoms of asthma in some individuals. If you notice your symptoms worsening, such as an increase in wheezing or shortness of breath, please seek immediate medical attention.
Neither Dupixent or Symbicort should be taken if you have been taking certain types of immunosuppressants. Be sure to always inform your physician about any medications you are currently taking; these drugs may require a period for clearance from the system to prevent dangerous interactions with both Dupixent and Symbicort.
In addition to this, it is important that patients using these medications regularly monitor their condition. If there is no improvement or if the condition gets worse after starting these medicines then medical help should be sought immediately. It's also crucial not to stop either medication abruptly without consulting a healthcare provider due to potential withdrawal effects.
How much do Dupixent and Symbicort cost?
For the brand name versions of these drugs:
- The price for two injections (300 mg each) of Dupixent is about $3,270, which works out to approximately $55 per day based on a bi-weekly regimen.
- A one-month supply (120 doses) of Symbicort inhaler can range from $250 to $350. Assuming twice daily use as typically recommended, this equates to roughly $8-$12 per day.
Thus, if you've been prescribed both medications and are deciding purely based on cost considerations, Symbicort would be more affordable than Dupixent. However, it's critical to remember that these medications have different indications and mechanisms of action - most importantly, they may not be interchangeable in treating your specific condition. Always consult with your healthcare provider before making medication decisions.
Please note: There are currently no generic equivalents available for either Dupixent or Symbicort in the U.S., so costs remain relatively high compared to other classes of medication.
Popularity of Dupixent and Symbicort
Dupilumab, sold under the brand name Dupixent, is a biologic medication used to treat moderate to severe cases of atopic dermatitis (eczema), asthma and chronic rhinosinusitis with nasal polyps. In 2020, it was estimated that about 400,000 people in the US were prescribed Dupixent.
Budesonide/formoterol fumarate dihydrate combination therapy, more commonly known by its brand name Symbicort, is an inhaler medication used for managing asthma and COPD symptoms. It contains two active ingredients: budesonide which reduces inflammation in the lungs; and formoterol fumarate dihydrate which relaxes muscles around your airways. The number of prescriptions for Symbicort has been relatively constant over recent years but remains significantly higher than those for Dupixent due in part to its wider application range including treating both Asthma and COPD patients – approximately 3 million U.S citizens received this drug during 2020.
While both drugs are effective within their respective domains, they cater to different patient profiles given that one treats skin conditions along with certain respiratory illnesses while the other is solely focused on lung-related ailments.
Conclusion
Both Dupixent (dupilumab) and Symbicort (budesonide/formoterol) are highly effective medications used to manage asthma and other respiratory conditions. Their efficacy is backed by a substantial body of clinical research, demonstrating better results than placebo treatments. While both drugs can be utilized in the same patient, this should only occur under careful medical supervision due to possible interactions.
Dupixent and Symbicort function differently; Dupixent works on two types of proteins known as interleukin-4 and interleukin-13 that are involved in inflammation processes, while Symbicort has dual action: budesonide reduces inflammation in the lungs, and formoterol helps relax the muscles around your airways for immediate relief from symptoms.
Symbicort is commonly prescribed first-line for those with moderate to severe asthma or COPD due to its immediate effect on symptoms whereas Dupixent may be considered if patients do not respond well to initial therapies or have specific allergic triggers causing their asthma.
Both medications come at a high cost but offer savings programs which can help alleviate some financial burdens for out-of-pocket expenses. It's important note that it may take some time before you feel the full benefits of these medications.
The side effects profiles vary between these two drugs: common ones associated with Symbicort include throat irritation and coughing, while eye issues such as conjunctivitis are more frequently reported with Dupixent use. As always, any troublesome side effects should be reported immediately to your healthcare provider.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Deeks, E. D. (2019, November). Dupilumab: A Review in Moderate to Severe Asthma. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-019-01221-x
- Aschenbrenner, D. S. (2022, September). New Indication for Dupilumab. AJN, American Journal of Nursing. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/01.naj.0000874100.31418.5d
- Berger, W. E., & Noonan, M. J. (2010, May). Treatment of Persistent Asthma With Symbicort® (Budesonide/Formoterol Inhalation Aerosol): An Inhaled Corticosteroid and Long-Acting β<sub>2</sub>-Adrenergic Agonist in One Pressurized Metered-Dose Inhaler. Journal of Asthma. Informa UK Limited.http://doi.org/10.3109/02770901003725684
- Buhl, R. (2003, August). Budesonide/formoterol for the treatment of asthma. Expert Opinion on Pharmacotherapy. Informa UK Limited.http://doi.org/10.1517/14656566.4.8.1393
- Scicchitano, R., Aalbers, R., Ukena, D., Manjra, A., Fouquert, L., Centanni, S., … Hultquist, C. (2004, July 22). Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion. Informa UK Limited.http://doi.org/10.1185/030079904x2051
- Emami, M., Tayebi, A., Gharipour, M., Farzamnia, S., & Temyarti, A. (2014). Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control. Advanced Biomedical Research. Medknow.http://doi.org/10.4103/2277-9175.127999
- Shirley, M. (2017, May 25). Dupilumab: First Global Approval. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-017-0768-3
- Price, D., Wirén, A., & Kuna, P. (2007, September 5). Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy. Wiley.http://doi.org/10.1111/j.1398-9995.2007.01466.x
- Halpin, D. M. (2008, January). Symbicort: a pharmacoeconomic review. Journal of Medical Economics. Informa UK Limited.http://doi.org/10.3111/13696990802210984